BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36306107)

  • 21. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
    Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
    Rymuza J; Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Nyc A; Baluszek S; Zieliński G; Kunicki J; Bujko M
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
    Di Muro G; Catalano R; Treppiedi D; Barbieri AM; Mangili F; Marra G; Di Bari S; Esposito E; Nozza E; Lania AG; Ferrante E; Locatelli M; Modena D; Steinkuhler C; Peverelli E; Mantovani G
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
    García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.
    Rai A; Yelamanchi SD; Radotra BD; Gupta SK; Mukherjee KK; Tripathi M; Chhabra R; Ahuja CK; Kumar N; Pandey A; Korbonits M; Dutta P; Gaston-Massuet C
    Acta Neuropathol Commun; 2022 Sep; 10(1):138. PubMed ID: 36114575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.
    Whyte E; Nezu M; Chik C; Tateno T
    Endocrinol Metab (Seoul); 2023 Dec; 38(6):631-654. PubMed ID: 37964483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower
    Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
    Li J; Wen S; Li B; Li N; Zhan X
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
    Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
    Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment.
    Aydin B; Arslan S; Bayraklı F; Karademir B; Arga KY
    Neuroendocrinology; 2022; 112(2):161-173. PubMed ID: 33706313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive pituitary tumors (PitNETs).
    Nishioka H
    Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular biology of thyrotroph pituitary neuroendocrine tumors.
    Horiguchi K
    Endocr J; 2023 Feb; 70(2):135-139. PubMed ID: 36653153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
    Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
    Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.
    Villa C; Vasiljevic A; Jaffrain-Rea ML; Ansorge O; Asioli S; Barresi V; Chinezu L; Gardiman MP; Lania A; Lapshina AM; Poliani L; Reiniger L; Righi A; Saeger W; Soukup J; Theodoropoulou M; Uccella S; Trouillas J; Roncaroli F
    Virchows Arch; 2019 Dec; 475(6):687-692. PubMed ID: 31578606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
    Asa SL
    Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; Venegas-Moreno E; L-López F; Fanciulli A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Dios E; Blanco-Acevedo C; Solivera J; Granata R; Kineman RD; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
    Neuroendocrinology; 2020; 110(11-12):1028-1041. PubMed ID: 31940630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
    Kurosaki M
    No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorescence-guided detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery available agents, their potential, and technical aspects.
    Vergeer RA; Theunissen REP; van Elk T; Schmidt I; Postma MR; Tamasi K; van Dijk JMC; Kuijlen JMA
    Rev Endocr Metab Disord; 2022 Jun; 23(3):647-657. PubMed ID: 35344185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.